[1] Northcott, P.A., Robinson, G.W., Kratz, C.P. et al. Medulloblastoma. Nat Rev Dis Primers 5, 11 (2019). https://doi.org/10.1038/s41572-019-0063-6
[2] Quinn T Ostrom, Ph.D, M.P.H, Haley Gittleman, M.S, Gabrielle Truitt, B.S, Alexander Boscia, B.S, Carol Kruchko, B.A, Jill S Barnholtz-Sloan, Ph.D, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015, Neuro-Oncology, Volume 20, Issue suppl_4, October 2018, Pages iv1–iv86, https://doi.org/10.1093/neuonc/noy131
[3] Louis, D.N., Perry, A., Reifenberger, G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131, 803–820 (2016). https://doi.org/10.1007/s00401-016-1545-1
[4] Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 Apr;123(4):465-72. doi: 10.1007/s00401-011-0922-z. Epub 2011 Dec 2. PMID: 22134537; PMCID: PMC3306779.
[5] Khatua S, Song A, Citla Sridhar D, Mack SC. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. Curr Neuropharmacol. 2018;16(7):1045-1058. doi: 10.2174/1570159X15666171129111324. PMID: 29189165; PMCID: PMC6120114.
[6] Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec;12(12):818-34. doi: 10.1038/nrc3410. PMID: 23175120; PMCID: PMC3889646.
[7] Northcott, P. A., Shih, D. J., Peacock, J., Garzia, L., Morrissy, A. S., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., Beroukhim, R., Ellison, D. W., Marshall, C. R., Lionel, A. C., Mack, S., Dubuc, A., Yao, Y., Ramaswamy, V., Luu, B., Rolider, A., … Taylor, M. D. (2012). Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 488(7409), 49–56. https://doi.org/10.1038/nature11327
[8] Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., Partap, S., Vogel, H., Taylor, M. D., Cho, Y. J., & Yeom, K. W. (2014). MRI surrogates for molecular subgroups of medulloblastoma. AJNR. American journal of neuroradiology, 35(7), 1263–1269. https://doi.org/10.3174/ajnr.A3990
[9] Castro, M. A., de Santiago, I., Campbell, T. M., Vaughn, C., Hickey, T. E., Ross, E., Tilley, W. D., Markowetz, F., Ponder, B. A., & Meyer, K. B. (2016). Regulators of genetic risk of breast cancer identified by integrative network analysis. Nature genetics, 48(1), 12–21. https://doi.org/10.1038/ng.3458
[10] Lim, W. K., Lyashenko, E., & Califano, A. (2009). Master regulators used as breast cancer metastasis classifier. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 504–515.
[11] Albanus, R. D., Juliani Siqueira Dalmolin, R., Alves Castro, M. A., Augusto de Bittencourt Pasquali, M., de Miranda Ramos, V., Pens Gelain, D., & Fonseca Moreira, J. C. (2013). Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression. PloS one, 8(12), e82457. https://doi.org/10.1371/journal.pone.0082457
[12] Fletcher, M. N., Castro, M. A., Wang, X., de Santiago, I., O'Reilly, M., Chin, S. F., Rueda, O. M., Caldas, C., Ponder, B. A., Markowetz, F., & Meyer, K. B. (2013). Master regulators of FGFR2 signalling and breast cancer risk. Nature communications, 4, 2464. https://doi.org/10.1038/ncomms3464
[13] Sartor, I. T., Zeidán-Chuliá, F., Albanus, R. D., Dalmolin, R. J., & Moreira, J. C. (2014). Computational analyses reveal a prognostic impact of TULP3 as a transcriptional master regulator in pancreatic ductal adenocarcinoma. Molecular bioSystems, 10(6), 1461–1468. https://doi.org/10.1039/c3mb70590k
[14] Fletcher, M. N., Castro, M. A., Wang, X., de Santiago, I., O'Reilly, M., Chin, S. F., Rueda, O. M., Caldas, C., Ponder, B. A., Markowetz, F., & Meyer, K. B. (2013). Master regulators of FGFR2 signalling and breast cancer risk. Nature communications, 4, 2464. https://doi.org/10.1038/ncomms3464
[15] Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res [Internet]. 2013 Jan 1 [cited 2017 Feb 24];41(D1):D991–5. Available from: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gks1193
[16] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015). “limma powers differential expression analyses for RNA-sequencing and microarray studies.” Nucleic Acids Research, 43(7), e47. doi: 10.1093/nar/gkv007.
[17] Robinson, G., Parker, M., Kranenburg, T. A., Lu, C., Chen, X., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., Chalhoub, N., Baker, S. J., Huether, R., Kriwacki, R., Curley, N., Thiruvenkatam, R., Wang, J., Wu, G., Rusch, M., Hong, X., … Gilbertson, R. J. (2012). Novel mutations target distinct subgroups of medulloblastoma. Nature, 488(7409), 43–48. https://doi.org/10.1038/nature11213
[18] Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC, Zlotnik A. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics. 2006 May;7(2):67-80. doi: 10.1007/s10048-006-0032-6. Epub 2006 Mar 30. PMID: 16572319.

[19] Carvalho BS, Irizarry RA (2010). “A Framework for Oligonucleotide Microarray Preprocessing.” Bioinformatics, 26(19), 2363-7. ISSN 1367-4803, doi: 10.1093/bioinformatics/btq431.

[20] Samuel A. Lambert, Arttu Jolma, Laura F. Campitelli, Pratyush K. Das, Yimeng Yin, Mihai Albu, Xiaoting Chen, Jussi Taipale, Timothy R. Hughes, Matthew T. Weirauch, The Human Transcription Factors, Cell, Volume 172, Issue 4, 2018, Pages 650-665, SSN 0092-8674, https://doi.org/10.1016/j.cell.2018.01.029.

[21] Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Dalla Favera, R., & Califano, A. (2006). ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC bioinformatics, 7 Suppl 1(Suppl 1), S7. https://doi.org/10.1186/1471-2105-7-S1-S7

[22] Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA (2014). “Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA Methylation microarrays.” Bioinformatics, 30(10), 1363–1369. doi: 10.1093/bioinformatics/btu049.

[23] Zhao, C., Zou, H., Zhang, J., Wang, J., & Liu, H. (2018). An integrated methylation and gene expression microarray analysis reveals significant prognostic biomarkers in oral squamous cell carcinoma. Oncology reports, 40(5), 2637–2647. https://doi.org/10.3892/or.2018.6702
[24] Kauffmann, A., Gentleman, R., & Huber, W. (2009). arrayQualityMetrics--a bioconductor package for quality assessment of microarray data. Bioinformatics (Oxford, England), 25(3), 415–416. https://doi.org/10.1093/bioinformatics/btn647
[25] Fisher, R.A. (1934). Statistical methods for research workers (5th ed.). Oliver and Boyd: Edinburgh.
[26] Wang, M., Zhao, Y., & Zhang, B. (2015). Efficient Test and Visualization of Multi-Set Intersections. Scientific reports, 5, 16923. https://doi.org/10.1038/srep16923
[27] Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Allen, J. C., Zagzag, D., Olson, J. M., Curran, T., Wetmore, C., Biegel, J. A., Poggio, T., Mukherjee, S., Rifkin, R., Califano, A., … Golub, T. R. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442. https://doi.org/10.1038/415436a
[28] Cavalli, F., Remke, M., Rampasek, L., Peacock, J., Shih, D., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq, H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., … Taylor, M. D. (2017). Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer cell, 31(6), 737–754.e6. https://doi.org/10.1016/j.ccell.2017.05.005
[29] Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H. J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D., Worst, B. C., Kool, M., … Lichter, P. (2017). The whole-genome landscape of medulloblastoma subtypes. Nature, 547(7663), 311–317. https://doi.org/10.1038/nature22973
[30] Inaguma, S., Riku, M., Hashimoto, M., Murakami, H., Saga, S., Ikeda, H., & Kasai, K. (2013). GLI1 interferes with the DNA mismatch repair system in pancreatic cancer through BHLHE41-mediated suppression of MLH1. Cancer research, 73(24), 7313–7323. https://doi.org/10.1158/0008-5472.CAN-13-2008
[31] Goodenberger, M. L., & Jenkins, R. B. (2012). Genetics of adult glioma. Cancer genetics, 205(12), 613–621. https://doi.org/10.1016/j.cancergen.2012.10.009
[32] He, Z., Yang, C., He, Y., Gong, B., Yin, C., Feng, J., Chen, L., Tang, J., & Chen, Y. (2021). CAMTA1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation. Cellular signalling, 79, 109882. https://doi.org/10.1016/j.cellsig.2020.109882
[33] Schraivogel, D., Weinmann, L., Beier, D., Tabatabai, G., Eichner, A., Zhu, J. Y., Anton, M., Sixt, M., Weller, M., Beier, C. P., & Meister, G. (2011). CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. The EMBO journal, 30(20), 4309–4322. https://doi.org/10.1038/emboj.2011.301
[34] Jeong, H. Y., Kim, H. J., Kim, C. E., Lee, S., Choi, M. C., & Kim, S. H. (2021). High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma. The International journal of neuroscience, 131(1), 7–14. https://doi.org/10.1080/00207454.2020.1732969
[35] Na, H., Han, J., Ka, N. L., Lee, M. H., Choi, Y. L., Shin, Y. K., & Lee, M. O. (2019). High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy. Breast cancer research : BCR, 21(1), 127. https://doi.org/10.1186/s13058-019-1197-x
[36] Lindström, S., Vachon, C. M., Li, J., Varghese, J., Thompson, D., Warren, R., Brown, J., Leyland, J., Audley, T., Wareham, N. J., Loos, R. J., Paterson, A. D., Rommens, J., Waggott, D., Martin, L. J., Scott, C. G., Pankratz, V. S., Hankinson, S. E., Hazra, A., Hunter, D. J., … Tamimi, R. M. (2011). Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nature genetics, 43(3), 185–187. https://doi.org/10.1038/ng.760
[37] Wang, C., Liu, S., Kuang, Y., Hu, X., & Fang, X. (2020). Downregulation of ZNF365 by methylation predicts poor prognosis in patients with colorectal cancer by decreasing phospho-p53 (Ser15) expression. Oncology letters, 20(4), 85. https://doi.org/10.3892/ol.2020.11946
[38] Cha, N., Liu, W., Yang, N., Xie, S., Gao, Y., Chen, X., Wang, X., & Ren, J. (2014). Oncogenicity of LHX4 in colorectal cancer through Wnt/β-catenin/TCF4 cascade. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(10), 10319–10324. https://doi.org/10.1007/s13277-014-2210-8
[39] Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., Rivers, C. S., Foo, C. K., Bhatt, D., Stinson, J., Gnad, F., Haverty, P. M., Gentleman, R., Chaudhuri, S., Janakiraman, V., Jaiswal, B. S., … Seshagiri, S. (2012). Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature genetics, 44(10), 1111–1116. https://doi.org/10.1038/ng.2405
[40] Ahlfeld, J., Favaro, R., Pagella, P., Kretzschmar, H. A., Nicolis, S., & Schüller, U. (2013). Sox2 requirement in sonic hedgehog-associated medulloblastoma. Cancer research, 73(12), 3796–3807. https://doi.org/10.1158/0008-5472.CAN-13-0238
[41] Elgaaen, B. V., Olstad, O. K., Sandvik, L., Odegaard, E., Sauer, T., Staff, A. C., & Gautvik, K. M. (2012). ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PloS one, 7(9), e46317. https://doi.org/10.1371/journal.pone.0046317
[42] Groeneveld, C. S., Chagas, V. S., Jones, S., Robertson, A. G., Ponder, B., Meyer, K. B., & Castro, M. (2019). RTNsurvival: an R/Bioconductor package for regulatory network survival analysis. Bioinformatics (Oxford, England), 35(21), 4488–4489. https://doi.org/10.1093/bioinformatics/btz229
